recast-jats-buildd8e1462159jitcJ Immunother Cancer40425Journal for ImmunoTherapy of CancerJ Immunother Cancer2051-1426BMJ Publishing Group Ltds40425-018-0487-748710.1186/s40425-018-0487-730635053/jitc/7/1/9.atomCorrectionCorrection to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patientsZhaoBin1aZhaoHong2bZhaoJiaxin3c 0000 0004 1764 2632grid.417384.dThe Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University Wenzhou China 0000 0004 1808 3502grid.412651.5The Third Affiliated Hospital of Harbin Medical University Harbin China grid.411491.8The Fourth Affiliated Hospital of Harbin Medical University Harbin China doctorbinzhao@126.com doctorhongzhao@126.com doctorzhaojiaxin@163.com 1220191112019181120191811201911120197191912201819122018© The Author(s).2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Following publication of the original article [1], the authors reported an error in their listed affiliations.

publisher-imprint-nameBioMed Centralvolume-issue-count1issue-article-count0issue-toc-levels0issue-pricelist-year2019issue-copyright-holderThe Author(s)issue-copyright-year2019article-contains-esmNoarticle-numbering-styleUnnumberedarticle-registration-date-year2018article-registration-date-month12article-registration-date-day19article-toc-levels0toc-levels0volume-typeRegularjournal-productArchiveJournalnumbering-styleUnnumberedarticle-grants-typeOpenChoicemetadata-grantOpenAccessabstract-grantOpenAccessbodypdf-grantOpenAccessbodyhtml-grantOpenAccessbibliography-grantOpenAccessesm-grantOpenAccessonline-firstfalsepdf-file-referenceBodyRef/PDF/40425_2018_Article_487.pdfpdf-typeTypesettarget-typeOnlinePDFissue-typeRegulararticle-typeErratumjournal-subject-primaryMedicine & Public Healthjournal-subject-secondaryOncologyjournal-subject-secondaryImmunologyjournal-subject-collectionMedicineopen-accesstrue

The original article can be found online at 10.1186/s40425-018-0421-z

Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:101

Doi 10.1186/s40425-018-0421-z

Following publication of the original article [1], the authors reported an error in their listed affiliations.

In this Correction Dr. Jiaxin Zhao is related to two affiliations:

1. The Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, China.

3. The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.

The published apologizes for any inconvenience caused by this error.

ReferenceZhao, et al. Journal for ImmunoTherapy of Cancer. 2018;6(101). 10.1186/s40425-018-0421-z.